fluoropyrimidine + oxaliplatin

Fluoropyrimidine + oxaliplatin is a chemotherapy drug combination used primarily in the treatment of various cancers, most notably colorectal and gastric cancers. The regimen typically includes a fluoropyrimidine (such as 5-fluorouracil or capecitabine) and oxaliplatin, a platinum-based chemotherapeutic agent. Fluoropyrimidines act as antimetabolites that inhibit DNA synthesis by targeting thymidylate synthase, while oxaliplatin forms DNA crosslinks that prevent replication and transcription, leading to cell death. This doublet regimen is often used as first-line therapy for metastatic colorectal cancer and advanced gastric cancer, either alone or with additional agents such as bevacizumab. The combination has demonstrated improved survival outcomes compared to some other regimens but is associated with specific toxicities including peripheral neuropathy (from oxaliplatin) and gastrointestinal side effects[2][3][5][6].

Other names

oxaliplatin–fluoropyrimidine combinationFP-OXOX-FP